A Phase 1 interventional study of RCT1100 in Primary Ciliary Dyskinesia, sponsored by ReCode Therapeutics. Completed at 4 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-29.
Sponsored by ReCode Therapeutics · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Ciliary Motility Disorders with a site in United States — 9 open to participants now, 11 under way, none of them phase 3. Ciliary Motility Disorders · United States.
Among the 28 studies in Ciliary Motility Disorders with a site in United States, this one is one of 5 that started in 2023, is one of 3 in phase 1, and was the 22nd registered.
80 studies on the registry are indexed under Ciliary Motility Disorders; 27 are open to participants now.
Browse Ciliary Motility Disorders studies →9 of the 28 studies in Ciliary Motility Disorders with a site in United States are open now. Recruiting first, the newest first:
Indiana University · Sites in United States
Ages 8–70 · Healthy volunteers
Connecticut Children's Medical Center · Sites in United States
Ages 2+
Indiana University · Sites in United States
Ages 6+ · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 2–99
The University of Texas Health Science Center, Houston · Sites in United States
Ages 4–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 21 Ciliary Motility Disorders studies recruiting now, 15 (71%) set no upper age limit and 3 (14%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 32 across 24 interventional studies indexed under Ciliary Motility Disorders.
Median enrollment 27 across the 9 interventional studies, 150 across the 19 observational. Of the 17 that completed or were terminated, 2 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 28 have an industry lead sponsor. The 10 most frequent:
ReCode Therapeutics is the lead sponsor of 6 studies on the registry; none are open to participants now.
ReCode Therapeutics has 5 studies filed under Ciliary Motility Disorders — fewer than ten, so there is no comparison to draw.
3 of the studies in Ciliary Motility Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03256773University of Alabama at BirminghamHigh Resolution Micro OCT Imaging | 2026-12-31 |
| NCT07699302University of North Carolina, Chapel HillClearance in Primary Ciliary Dyskinesia | 2027-01 |
| NCT00807482University of North Carolina, Chapel HillPathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies in Ciliary Motility Disorders with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is the first-in-human study with RCT1100 and is designed to provide initial safety and tolerability data for future clinical studies.
The primary objective of this study is to assess the safety and tolerability of a single ascending dose of inhaled RCT1100 administered via nebulizer to healthy participants and patients with Primary Ciliary Dyskinesia caused by a pathogenic mutation in the DNAI1 Gene.
Major Inclusion Criteria:
Major Exclusion Criteria:
Laboratory abnormalities in clinical laboratory tests at screening:
Other protocol defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: RCT1100 single dose
Drug: RCT1100
RCT1100 mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer
The number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs).
Safety and tolerability as assessed by number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), as well as an adverse event of special interest (AESI): "Fever", which will include body temperature and any associated symptoms (chills, myalgia).
Time frame: From Baseline Through Day 180
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2023 to primary completion in Jul 2024, 17 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: RCT1100
ReCode Therapeutics